Chinese Expert Consensus on the Use of Biologics in Patients with Chronic Rhinosinusitis (2022, Zhuhai).
Hong HY, Chen TY, Yang QT, Sun YQ, Chen FH, Lou HF, Wang HT, Yu RL, An YF, Liu F, Wang TS, Lu MP, Qiu QH, Wang XD, Chen JJ, Meng CD, Xie ZH, Meng J, Zeng M, Xu CL, Wang Y, Yang YC, Zhang WT, Tang J, Yang YL, Xu R, Yu GD, Shi ZH, Wei X, Ye HP, Sun YN, Yu SQ, Zhang TH, Yong J, Hang W, Xu YT, Xu Y, Tan GL, Sun N, Yang G, Li YJ, Ye J, Zuo KJ, Zhang LQ, Wang XY, Yang AN, Xu YX, Liao W, Fan YP, Li HB.
Hong HY, et al.
ORL J Otorhinolaryngol Relat Spec. 2023;85(3):128-140. doi: 10.1159/000529918. Epub 2023 Apr 5.
ORL J Otorhinolaryngol Relat Spec. 2023.
PMID: 37019094
Free article.
Review.
CRS with nasal polyps (CRSwNP), an important phenotype of CRS, has a high recurrence rate even after receiving corticosteroids and/or functional endoscopic sinus surgery. In recent years, clinicians have focused on the application of biological agents in CRSwNP. ...Biologi …
CRS with nasal polyps (CRSwNP), an important phenotype of CRS, has a high recurrence rate even after receiving corticosteroids and/or functi …